Datopotamab Deruxtecan vs LCB84
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04656652 · Phase 3 · active, not recruiting
This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).
Next expected readout: January 2027 · NCT06417814 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)
Result source: NCT04656652
LCB84
Developed by Janssen and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Datopotamab Deruxtecan | LCB84 |
|---|---|---|
| PFS, median | 4.4 vs 3.7vs DocetaxelNCT046566521 other result
| —Not reported |
| OS, median | 12.9 vs 11.8vs DocetaxelNCT04656652 | —Not reported |
| ORR | 35.8%bNCT04484142 | —Not reported |
| Duration of response, median | —Trial running · NCT04656652 | —Not reported |
PFS, median
- Datopotamab Deruxtecan
- 4.4 vs 3.7vs DocetaxelNCT04656652
1 other result
- 4.4 vs 3 NCT04656652
- LCB84
- —Not reported
OS, median
- Datopotamab Deruxtecan
- 12.9 vs 11.8vs DocetaxelNCT04656652
- LCB84
- —Not reported
ORR
- Datopotamab Deruxtecan
- 35.8%bNCT04484142
- LCB84
- —Not reported
Duration of response, median
- Datopotamab Deruxtecan
- —Trial running · NCT04656652
- LCB84
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
LCB84: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Datopotamab Deruxtecan: 4 of 4 rows · LCB84: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan |
|---|---|
| Dropout rate | 77.3%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result85.4%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Discontinued due to AEs | —6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result9.5%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Serious AEs | 31%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result24.8%6.0 mg/kg Q3W NCT04484142 · Phase 2 |
| Most frequent reported AEs | 6.0 mg/kga stomatitis 49.8% nausea 37.7% alopecia 32% NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · LCB84's landscape